{"gene":"DYRK1A","run_date":"2026-06-09T23:54:42","timeline":{"discoveries":[{"year":2001,"finding":"DYRK1A (and DYRK2) phosphorylates eIF2Bepsilon at Ser539 in vitro, priming it for subsequent GSK3 phosphorylation at Ser535; DYRK1A also phosphorylates tau at Thr212 in vitro, priming tau for GSK3 phosphorylation at Ser208, establishing DYRK1A as a GSK3-priming kinase.","method":"In vitro kinase assays with recombinant proteins; comparison across multiple proline-directed kinases; in vivo phosphorylation state analysis","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with multiple substrates and kinase comparisons, combined with in vivo validation of Ser539 phosphorylation state","pmids":["11311121"],"is_preprint":false},{"year":2001,"finding":"DYRK1A directly phosphorylates CREB during neuronal differentiation of hippocampal progenitor cells, leading to stimulation of CRE-mediated gene transcription; DYRK1A activity is induced by bFGF and specifically binds active CREB.","method":"In vitro kinase assay; co-immunoprecipitation; reporter gene assay; dominant-negative blockade of DYRK1A in H19-7 cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct phosphorylation demonstrated in vitro plus cellular functional readout (neurite outgrowth, CREB phosphorylation), single lab","pmids":["11518709"],"is_preprint":false},{"year":2002,"finding":"DYRK1A (Dyrk1) enhances Gli1-dependent transcriptional activity in the nucleus by retaining Gli1 in the nucleus and increasing its transcriptional activity independently of nuclear export; DYRK1A acts synergistically with Sonic hedgehog signaling but is not regulated by Shh.","method":"Reporter gene assays; nuclear localization assays; co-expression studies in C3H10T1/2 cells; kinase activity assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cellular assays showing nuclear retention and transcriptional enhancement, single lab","pmids":["12138125"],"is_preprint":false},{"year":2002,"finding":"Dyrk1A haploinsufficiency in mice causes decreased brain size, increased neuronal densities in specific regions, reduced neuron numbers in superior colliculus, and neonatal lethality of nulls at midgestation, establishing a nonredundant vital role in brain growth.","method":"Gene targeting (knockout mouse); cell counting; histological analysis; neurobehavioral testing","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function with specific quantitative phenotypic readouts in vivo, well-replicated model","pmids":["12192061"],"is_preprint":false},{"year":2004,"finding":"14-3-3 protein interacts with the N-terminus of DYRK1A independently of DYRK1A phosphorylation status, and this binding increases DYRK1A kinase activity in a dose-dependent manner in vitro; a peptide inhibiting 14-3-3 binding decreased DYRK1A activity in COS7 cells.","method":"Yeast two-hybrid screen; in vitro binding assay; in vitro kinase assay; co-immunoprecipitation; cell-based kinase assay with inhibitory peptide","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal binding confirmed in vitro and in vivo, functional kinase modulation demonstrated, single lab","pmids":["15369779"],"is_preprint":false},{"year":2005,"finding":"DYRK1A selectively binds and phosphorylates HIP-1 (huntingtin-interacting protein 1) during neuronal differentiation; DYRK1A-mediated phosphorylation of HIP-1 blocks HIP-1-mediated cell death and enhances neurite outgrowth; upon apoptotic stimulation (etoposide), HIP-1 dissociates from DYRK1A and binds caspase-3, promoting its activation.","method":"Co-immunoprecipitation; in vitro kinase assay; cell death assays; neurite outgrowth measurement in H19-7 cells","journal":"Journal of neuroscience research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct phosphorylation demonstrated in vitro, binding and functional consequences shown in cells, single lab","pmids":["15906374"],"is_preprint":false},{"year":2008,"finding":"DYRK1A phosphorylates caspase-9 on threonine residue 125, and this phosphorylation event is required to protect retina cells from apoptotic cell death during development; changes in Dyrk1a gene dosage strongly alter inner retina layer cellularity without affecting proliferation or specification of progenitors.","method":"In vitro kinase assay; gene dosage manipulation (knockout/overexpression mice); retinal cell counting; functional electroretinography","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct phosphorylation site identified in vitro with in vivo genetic dosage validation and functional phenotypic readouts","pmids":["19081073"],"is_preprint":false},{"year":2009,"finding":"Harmine is a potent and selective inhibitor of DYRK1A (IC50 ~33 nM for substrate phosphorylation in vitro), inhibiting DYRK1A more potently than DYRK1B, DYRK2, or DYRK4; harmine inhibits DYRK1A substrate phosphorylation in cultured cells (IC50 ~48 nM) and interferes with neuritogenesis in hippocampal neurons.","method":"In vitro kinase assay; in vitro bacterial translation system; cell-based substrate phosphorylation assay; hippocampal neuron culture with neurite analysis","journal":"The FEBS journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — quantitative in vitro and cellular assays with multiple substrates and kinase family members compared, replicated by multiple subsequent studies","pmids":["19796173"],"is_preprint":false},{"year":2010,"finding":"DYRK1A directly phosphorylates SIRT1 at Thr522, activating its deacetylase activity by promoting product release and increasing enzymatic turnover; activated SIRT1 deacetylates p53, promoting cell survival; knockdown of DYRK1A leads to hypophosphorylation of SIRT1 and sensitizes cells to DNA damage-induced death.","method":"In vitro kinase assay; phosphomimetic/dephosphorylation mimetic mutants; deacetylase activity assays; siRNA knockdown; apoptosis assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with phosphosite mutagenesis and enzymatic activity readout; multiple orthogonal assays in one study","pmids":["20167603"],"is_preprint":false},{"year":2011,"finding":"DYRK1A specifically phosphorylates LIN52 on serine residue 28, and this phosphorylation is required for DREAM complex assembly (containing p130, E2F4, DP1, and MuvB core proteins); inhibiting DYRK1A activity or mutating LIN52 S28 disrupts DREAM assembly and impairs entry into quiescence and Ras-induced senescence.","method":"Mass spectrometric phosphopeptide identification; in vitro kinase assay with point mutants; co-immunoprecipitation of DREAM components; quiescence and senescence assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 / Strong — phosphosite identified by MS and confirmed by in vitro kinase assay with mutagenesis, functional consequence validated in multiple cellular contexts","pmids":["21498570"],"is_preprint":false},{"year":2011,"finding":"DYRK1A directly interacts with and phosphorylates RCAN1 at Ser112 and Thr192; phosphorylation at Ser112 primes RCAN1 for GSK3β phosphorylation at Ser108; phosphorylation at Thr192 enhances RCAN1 inhibition of calcineurin phosphatase activity, reduces NFAT transcriptional activity, extends RCAN1 half-life, and enhances tau phosphorylation.","method":"Co-immunoprecipitation; in vitro kinase assay; calcineurin phosphatase activity assay; NFAT reporter assay; protein half-life measurement; immunohistochemistry in transgenic mice","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct phosphorylation at two sites demonstrated in vitro, functional consequences of each site validated in cells and in transgenic mice","pmids":["21965663"],"is_preprint":false},{"year":2011,"finding":"DYRK1A positively regulates the ASK1-JNK signaling pathway during apoptotic cell death; DYRK1A directly interacts with and phosphorylates ASK1, promoting ASK1-mediated JNK1 activation.","method":"Co-immunoprecipitation; in vitro kinase assay; JNK activity assay; apoptosis induction in neuronal cells","journal":"Experimental neurobiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct interaction and phosphorylation shown in vitro plus functional pathway activation in cells, single lab","pmids":["22110360"],"is_preprint":false},{"year":2013,"finding":"DYRK1A enhances tau mRNA stability (not transcription) to increase tau expression in a dose-dependent, kinase-activity-independent manner, preferentially increasing exon 10-containing isoforms.","method":"RT-PCR and Western blot for tau mRNA/protein; co-expression in HEK-293FT cells; kinase-dead mutant; mRNA stability assay; analysis of Ts65Dn mouse brains","journal":"Journal of Alzheimer's disease : JAD","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinase-dead mutant distinguishes kinase-independent mechanism; mRNA stability measured directly; confirmed in vivo in trisomy mice","pmids":["23948904"],"is_preprint":false},{"year":2016,"finding":"DYRK1A interacts with all members of the D-cyclin family and represses their protein levels; specifically, forced DYRK1A expression increases phosphorylation of Cyclin D2 (Ccnd2) at Thr280, promoting its proteasomal degradation; this results in hypo-phosphorylated Rb1, suppressed Rb/E2F signaling, and impaired cardiomyocyte cell cycle progression.","method":"Transgenic cardiac-specific overexpression mouse; co-immunoprecipitation; in vitro kinase assay; Western blot for cyclin levels; proteasome inhibitor rescue; E2F target gene expression analysis","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — phosphorylation site identified (Thr280), proteasomal degradation confirmed, downstream Rb/E2F signaling pathway characterized in vivo transgenic model","pmids":["27056896"],"is_preprint":false},{"year":2018,"finding":"DYRK1A interacts with histone acetyltransferases p300 and CBP; overexpression of DYRK1A causes hyperphosphorylation of p300 and CBP; DYRK1A co-localizes genome-wide with p300 and CBP at enhancers and near transcription start sites; DYRK1A knockdown reduces H3K27 acetylation at enhancers, indicating DYRK1A modulates p300/CBP activity at enhancers.","method":"Proteomics/mass spectrometry; co-immunoprecipitation; ChIP-sequencing; shRNA knockdown and overexpression; H3K27ac ChIP-seq","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods (proteomics, reciprocal Co-IP, genome-wide ChIP-seq, functional KD), single lab","pmids":["30137413"],"is_preprint":false},{"year":2018,"finding":"DYRK1A positively regulates VEGF-dependent NFAT transcriptional responses in endothelial cells by maintaining VEGFR2 accumulation; DYRK1A silencing reduces intracellular Ca2+ influx in response to VEGF, dampening PLCγ1 activation and NFAT signaling; Dyrk1a heterozygous mice show defects in developmental retinal vascularization.","method":"siRNA silencing in primary endothelial cells; Ca2+ imaging; NFAT reporter assay; VEGFR2 accumulation assay; PLCγ1 phosphorylation; retinal vascularization in heterozygous mice","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal cellular assays plus in vivo genetic validation in heterozygous mice","pmids":["29742440"],"is_preprint":false},{"year":2019,"finding":"DYRK1A undergoes proteolytic processing in Alzheimer's disease patient hippocampus; truncated forms accumulate in astrocytes and exhibit increased affinity towards STAT3α; proteolysis modifies DYRK1A kinase substrate specificity without abolishing kinase activity.","method":"Western blot of human AD and control hippocampus; immunohistochemistry; in vitro proteolysis assay; substrate affinity comparison; APP/PS1 mouse model analysis","journal":"Acta neuropathologica communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic finding in human tissue confirmed in mouse model with biochemical substrate specificity characterization, single lab","pmids":["30885273"],"is_preprint":false},{"year":2021,"finding":"DYRK1A phosphorylates FOXO1 and STAT3 to support B-ALL development; genetic and pharmacological inhibition of DYRK1A decreases leukemic cell expansion; loss of DYRK1A-mediated FOXO1/STAT3 signaling disrupts DNA damage and ROS regulation, leading to preferential cell death in leukemic B cells.","method":"Genetic knockdown and pharmacological inhibition; in vitro and in vivo leukemia models; substrate phosphorylation assays; ROS and DNA damage assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct substrate identification with genetic and pharmacological validation in vitro and in vivo, multiple orthogonal methods","pmids":["33393494"],"is_preprint":false},{"year":2021,"finding":"DYRK1A phosphorylates TRAF3 at serine-29 to interfere with TRAF3-mediated NIK (NF-κB-inducing kinase) degradation, thereby facilitating BAFF-induced NIK accumulation and noncanonical NF-κB activation in B cells.","method":"Co-immunoprecipitation; in vitro kinase assay; genetic knockdown/knockout; noncanonical NF-κB pathway activation assays; mouse model of lupus and B-ALL","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — phosphosite identified (S29), mechanistic pathway established from substrate phosphorylation to NIK accumulation and NF-κB activation, validated in vivo","pmids":["34255829"],"is_preprint":false},{"year":2021,"finding":"PPM1B (a PP2C family Ser/Thr phosphatase) dephosphorylates DYRK1A at Ser258, inhibiting DYRK1A activity; DYRK1A autophosphorylates Ser258; PPM1B-mediated dephosphorylation reduces DYRK1A-dependent tau phosphorylation at Thr212 and inhibits toxic tau oligomerization.","method":"LC-MS/MS identification of DYRK1A-binding proteins; in vitro kinase/phosphatase assays; co-immunoprecipitation; tau phosphorylation and aggregation assays in HEK293 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — autophosphorylation site and phosphatase identified biochemically, functional consequence on downstream substrate (tau) demonstrated with mechanistic clarity","pmids":["33380426"],"is_preprint":false},{"year":2021,"finding":"TRAF2 (E3 ligase) binds the PVQE motif of DYRK1A (between PEST and histidine repeat domain) and mediates K63-linked ubiquitination of DYRK1A, causing its translocation to vesicle membranes; vesicle-localized DYRK1A phosphorylates Sprouty 2, inhibiting EGFR degradation.","method":"Co-immunoprecipitation; ubiquitination assays (K63-linkage specific); subcellular fractionation; vesicle localization studies; EGFR degradation assays; DYRK1A knockdown","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — K63 ubiquitination and vesicle translocation demonstrated biochemically; functional downstream consequence shown; single lab","pmids":["34117217"],"is_preprint":false},{"year":2021,"finding":"DYRK1A promotes DYRK1A-CDK5-SOX2 axis in glioblastoma: DYRK1A deactivates CDK5 to decrease SOX2 expression and promote GSC differentiation commitment; DYRK1A inhibition insulates GSCs from differentiation signals by maintaining CDK5/SOX2 activity.","method":"siRNA knockdown; pharmacological inhibition; CDK5 activity assays; SOX2 expression analysis; glioblastoma stem cell self-renewal assays","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — pathway placed by genetic manipulation and kinase inhibition in cell lines, CDK5 as intermediary inferred from activity assays, single lab","pmids":["33924599"],"is_preprint":false},{"year":2021,"finding":"TROAP directly binds DYRK1A/B and causes cytoplasmic retention of DYRK1A/B, promoting cell cycle progression via activation of Akt/GSK-3β signaling in hepatocellular carcinoma cells.","method":"Co-immunoprecipitation; subcellular fractionation/localization assays; shRNA knockdown; Akt/GSK-3β pathway activation assays; in vitro and in vivo tumor growth assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding and relocalization shown biochemically with functional consequence in cells and in vivo, single lab","pmids":["33500384"],"is_preprint":false},{"year":2023,"finding":"DYRK1A promotes viral entry of SARS-CoV, SARS-CoV-2, and MERS-CoV in a kinase-independent manner by regulating ACE2 and DPP4 transcription; DYRK1A promotes DNA accessibility at the ACE2 promoter and a putative distal enhancer.","method":"Genome-wide CRISPR/Cas9 screen; kinase-dead mutant rescue; ATAC-seq for chromatin accessibility; ACE2/DPP4 expression assays; viral entry assays in human and non-human primate cells","journal":"PLoS biology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — kinase-dead mutant establishes kinase-independent mechanism; ATAC-seq provides mechanistic basis; validated across species","pmids":["37310920"],"is_preprint":false},{"year":2023,"finding":"DYRK1A identifies ABLIM3 (a cytoskeletal protein) as a synaptic substrate in hippocampal mossy fiber-PV interneuron synapses; DYRK1A recruits feedforward inhibition of CA3 and CA2 via PV interneurons to promote social recognition; Ablim3 downregulation rescues PV IN-mediated inhibition and social behavior in Dyrk1a heterozygous mice.","method":"Genetic epistasis; viral knockdown of Ablim3 in dentate granule cells; chemogenetic activation of PV INs; electrophysiology; behavioral assays in Dyrk1a+/- mice","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic epistasis identifies ABLIM3 as substrate; circuit-level mechanism established with multiple orthogonal approaches (chemogenetics, genetics, behavior)","pmids":["37797581"],"is_preprint":false},{"year":1997,"finding":"The murine Dyrk protein localizes to the cell nucleus, can self-associate (via leucine zipper), and maps to distal chromosome 16 (syntenic with human 21q22.2).","method":"Two-hybrid self-interaction assay; subcellular fractionation/immunostaining; chromosomal mapping by interspecific backcross","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct nuclear localization by fractionation; self-association confirmed in two-hybrid; foundational characterization paper","pmids":["9070862"],"is_preprint":false},{"year":1999,"finding":"DYRK1A is activated by tyrosine autophosphorylation in the activation loop (between subdomains VII and VIII) and subsequently phosphorylates exogenous substrates exclusively on serine/threonine residues; this dual-specificity mechanism is a defining biochemical property of the DYRK family.","method":"In vitro kinase assay; autophosphorylation analysis; substrate specificity profiling","journal":"Progress in nucleic acid research and molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical mechanism replicated across multiple labs and confirmed by subsequent structural and mutagenesis studies","pmids":["9932450"],"is_preprint":false},{"year":2018,"finding":"DYRK1A phosphorylates α-synuclein at serine 129 (Ser129), and Dyrk1a knockdown reduces P-α-synuclein (Ser129) levels and activates the PI3K/AKT pathway, reducing dopaminergic neuron apoptosis in a Parkinson's disease model.","method":"AAV-shRNA knockdown of Dyrk1a in vivo; Western blot for P-α-synuclein Ser129; apoptosis markers; transcriptome and metabolome sequencing","journal":"Parkinson's disease","confidence":"Low","confidence_rationale":"Tier 3 / Weak — in vivo knockdown shows correlation between Dyrk1a levels and α-synuclein phosphorylation but direct in vitro phosphorylation not demonstrated in this abstract; single study","pmids":["37469393"],"is_preprint":false},{"year":2018,"finding":"DYRK1A stabilizes the c-MET receptor through SPRY2, leading to prolonged activation of ERK signaling in pancreatic ductal adenocarcinoma; DYRK1A protein level positively correlates with c-MET levels.","method":"Knockdown experiments in PDAC cell lines; DYRK1A genetic reduction in mouse PDAC models; co-expression and protein stability analysis; ERK signaling measurement","journal":"Gut","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanism defined through genetic knockdown in vitro and in vivo, SPRY2-mediated pathway established, single lab","pmids":["30343272"],"is_preprint":false}],"current_model":"DYRK1A is a dual-specificity kinase that undergoes obligatory cotranslational tyrosine autophosphorylation in its activation loop to achieve full activity, after which it phosphorylates substrates exclusively on serine/threonine residues; it functions as a priming kinase for GSK3 on multiple substrates (eIF2Bε, tau, RCAN1), directly phosphorylates transcriptional regulators (CREB, Gli1, LIN52, FOXO1, STAT3), cell cycle proteins (caspase-9, Cyclin D2), survival factors (SIRT1, HIP-1, ASK1), and signaling pathway components (TRAF3, SPRY2), and its activity is regulated by 14-3-3 binding (activation), PPM1B-mediated dephosphorylation at Ser258 (inhibition), TRAF2-mediated K63-ubiquitination (vesicle translocation), and TROAP interaction (cytoplasmic retention); nuclear DYRK1A regulates DREAM complex assembly, enhancer activity via p300/CBP phosphorylation, and ACE2/DPP4 transcription in a kinase-independent manner, collectively establishing DYRK1A as a pleiotropic regulator of neuronal development, cell cycle, apoptosis, immunity, and angiogenesis whose gene dosage is critical in Down syndrome and related neurodevelopmental disorders."},"narrative":{"mechanistic_narrative":"DYRK1A is a dual-specificity protein kinase that serves as a pleiotropic regulator of neuronal development, cell cycle progression, apoptosis, immunity, and angiogenesis, with its gene dosage critically constrained in brain development [PMID:12192061, PMID:9932450]. It achieves activity through tyrosine autophosphorylation in its activation loop and thereafter phosphorylates exogenous substrates exclusively on serine/threonine residues [PMID:9932450]. A recurring biochemical theme is its action as a priming kinase that creates GSK3 phosphorylation sites, demonstrated for eIF2Bepsilon, tau, and RCAN1 [PMID:11311121, PMID:21965663]. Through direct substrate phosphorylation DYRK1A controls transcriptional programs (CREB, Gli1, the DREAM-complex subunit LIN52, FOXO1, STAT3) and couples to cell-cycle and survival machinery: it phosphorylates LIN52 at Ser28 to enable DREAM complex assembly and entry into quiescence/senescence [PMID:21498570], phosphorylates caspase-9 at Thr125 and SIRT1 at Thr522 to favor cell survival [PMID:19081073, PMID:20167603], and represses D-cyclins by phosphorylating Cyclin D2 (Thr280) to drive its degradation and suppress Rb/E2F signaling [PMID:27056896]. In the immune compartment it sustains B-lineage malignancy via FOXO1/STAT3 phosphorylation and activates noncanonical NF-kappaB by phosphorylating TRAF3 at Ser29 to block NIK degradation [PMID:33393494, PMID:34255829]. DYRK1A activity and localization are tuned by multiple inputs: 14-3-3 binding enhances activity, PPM1B dephosphorylates the autophosphorylation site Ser258 to inhibit it, TRAF2-mediated K63 ubiquitination relocalizes it to vesicles, and TROAP enforces cytoplasmic retention [PMID:15369779, PMID:33380426, PMID:34117217, PMID:33500384]. In addition to its catalytic roles, DYRK1A exerts kinase-independent functions, stabilizing tau mRNA and promoting chromatin accessibility at the ACE2/DPP4 loci to enable coronavirus entry [PMID:23948904, PMID:37310920], and it modulates enhancer activity through phosphorylation of the acetyltransferases p300/CBP [PMID:30137413]. Several findings tie DYRK1A to neurological disease: it primes tau phosphorylation relevant to Alzheimer pathology and undergoes proteolytic processing in AD hippocampus that retunes its substrate specificity toward STAT3alpha [PMID:11311121, PMID:30885273, PMID:33380426].","teleology":[{"year":1997,"claim":"Established the basic cell biology of the protein — where it acts and that it oligomerizes — placing it on the Down syndrome critical region of chromosome 21.","evidence":"Subcellular fractionation, two-hybrid self-interaction, and interspecific backcross mapping of murine Dyrk","pmids":["9070862"],"confidence":"Medium","gaps":["No catalytic activity or substrate defined","Functional consequence of self-association unknown"]},{"year":1999,"claim":"Defined the defining catalytic mechanism — resolving how a kinase with tyrosine autophosphorylation acts only as a Ser/Thr kinase on substrates.","evidence":"In vitro kinase assays with autophosphorylation analysis and substrate specificity profiling","pmids":["9932450"],"confidence":"High","gaps":["Cotranslational nature of autophosphorylation not addressed here","No physiological substrates identified at this stage"]},{"year":2001,"claim":"Identified DYRK1A as a GSK3-priming kinase and a direct activator of CRE-dependent transcription, linking it to both tau biology and neuronal differentiation.","evidence":"In vitro kinase assays on eIF2Bepsilon/tau with cross-kinase comparison; Co-IP, reporter assays, and dominant-negative blockade in hippocampal progenitor cells","pmids":["11311121","11518709"],"confidence":"High","gaps":["CREB phosphorylation site and selectivity defined by single lab","Relative in vivo contribution of priming vs direct phosphorylation unresolved"]},{"year":2002,"claim":"Genetic loss-of-function and a transcriptional readout together established a nonredundant, dosage-sensitive role in brain growth and Gli1-dependent transcription.","evidence":"Dyrk1A knockout mouse with histology and cell counting; reporter and nuclear localization assays in C3H10T1/2 cells","pmids":["12192061","12138125"],"confidence":"High","gaps":["Molecular substrates driving the brain phenotype not identified","Mechanism of Gli1 nuclear retention not biochemically resolved"]},{"year":2004,"claim":"Showed DYRK1A activity is regulated post-translationally by a protein interaction, revealing 14-3-3 as a positive modulator independent of phosphorylation status.","evidence":"Yeast two-hybrid, in vitro binding/kinase assays, and inhibitory-peptide cell assay","pmids":["15369779"],"confidence":"Medium","gaps":["Structural basis of activation unknown","Physiological contexts where 14-3-3 regulation operates not defined"]},{"year":2005,"claim":"Extended DYRK1A into apoptotic control of neuronal differentiation by identifying HIP-1 as a substrate whose phosphorylation suppresses cell death.","evidence":"Co-IP, in vitro kinase assay, cell-death and neurite outgrowth assays in H19-7 cells","pmids":["15906374"],"confidence":"Medium","gaps":["Phosphosite on HIP-1 not mapped","Single-lab cellular evidence"]},{"year":2008,"claim":"Connected DYRK1A directly to apoptotic machinery in vivo by identifying caspase-9 Thr125 phosphorylation as dosage-sensitive protection of developing retina.","evidence":"In vitro kinase assay with site identification plus knockout/overexpression mice and electroretinography","pmids":["19081073"],"confidence":"High","gaps":["Generality beyond retina untested","Interplay with other caspase-9 regulators not addressed"]},{"year":2009,"claim":"Provided a selective chemical-genetic tool (harmine) enabling pharmacological dissection of DYRK1A in cells and neurons.","evidence":"Quantitative in vitro kinase assays across DYRK family, cell-based substrate assays, and hippocampal neuron neuritogenesis","pmids":["19796173"],"confidence":"High","gaps":["Off-target activity of harmine on other kinases","Does not distinguish kinase-dependent from kinase-independent functions"]},{"year":2010,"claim":"Defined a survival axis whereby DYRK1A phosphorylates SIRT1 (Thr522) to enhance its deacetylase turnover and p53 deacetylation, protecting cells from DNA-damage death.","evidence":"In vitro kinase assays, phosphosite mutants, deacetylase activity assays, siRNA knockdown, apoptosis assays","pmids":["20167603"],"confidence":"High","gaps":["In vivo relevance of SIRT1 axis not tested","Single-study mechanism"]},{"year":2011,"claim":"Established DYRK1A as a cell-cycle controller and broadened its priming-kinase and apoptotic roles by identifying LIN52 (DREAM assembly), RCAN1, and ASK1 as substrates.","evidence":"MS phosphosite mapping plus in vitro kinase assays with mutagenesis; DREAM Co-IP and quiescence/senescence assays; calcineurin and NFAT assays; JNK pathway assays","pmids":["21498570","21965663","22110360"],"confidence":"High","gaps":["How DYRK1A access to nuclear vs cytoplasmic substrates is controlled","ASK1 finding rests on single-lab cellular evidence"]},{"year":2013,"claim":"Revealed a kinase-independent function — stabilization of tau mRNA favoring exon-10 isoforms — distinguishing DYRK1A's catalytic from non-catalytic contributions to tau pathology.","evidence":"Kinase-dead mutant, mRNA stability assays in HEK-293FT, and analysis of Ts65Dn mouse brain","pmids":["23948904"],"confidence":"Medium","gaps":["RNA-binding mechanism unknown","Whether DYRK1A binds tau mRNA directly not shown"]},{"year":2016,"claim":"Showed DYRK1A restrains the cell cycle by phosphorylating Cyclin D2 (Thr280) for degradation and suppressing Rb/E2F, explaining impaired cardiomyocyte proliferation.","evidence":"Cardiac-specific overexpression mice, Co-IP, in vitro kinase assay, proteasome rescue, E2F target analysis","pmids":["27056896"],"confidence":"High","gaps":["Endogenous-dosage relevance vs overexpression unclear","Specificity among D-cyclins partially resolved"]},{"year":2018,"claim":"Expanded DYRK1A into chromatin/enhancer regulation and angiogenesis via p300/CBP phosphorylation and VEGFR2-dependent NFAT signaling.","evidence":"Proteomics, reciprocal Co-IP, ChIP-seq and H3K27ac ChIP-seq with knockdown; endothelial Ca2+ imaging, NFAT reporters, and heterozygous-mouse retinal vascularization","pmids":["30137413","29742440"],"confidence":"High","gaps":["Direct p300/CBP phosphosites and functional consequences not fully mapped","Mechanism of VEGFR2 maintenance not at molecular resolution"]},{"year":2018,"claim":"Linked DYRK1A to oncogenic receptor signaling in solid tumors by stabilizing c-MET through SPRY2 and prolonging ERK activation.","evidence":"Knockdown in PDAC cell lines and mouse models with protein stability and ERK signaling analysis","pmids":["30343272"],"confidence":"Medium","gaps":["Direct phosphorylation events in the SPRY2/c-MET axis not defined here","Single-lab"]},{"year":2019,"claim":"Demonstrated that disease-associated proteolytic processing of DYRK1A retunes substrate specificity, accumulating in AD astrocytes with enhanced STAT3alpha affinity.","evidence":"Western blot/IHC of human AD hippocampus, in vitro proteolysis, substrate affinity comparison, APP/PS1 mouse analysis","pmids":["30885273"],"confidence":"Medium","gaps":["Protease responsible not identified","Functional output of STAT3alpha rewiring in vivo unclear"]},{"year":2021,"claim":"A burst of studies defined DYRK1A's immune/oncogenic substrates (FOXO1/STAT3, TRAF3-Ser29) and a regulatory network (PPM1B dephosphorylation of Ser258, TRAF2 K63-ubiquitination/vesicle targeting, TROAP cytoplasmic retention, CDK5-SOX2 axis).","evidence":"Genetic/pharmacological leukemia models; Co-IP and in vitro kinase/phosphatase/ubiquitination assays; subcellular fractionation; GSC self-renewal and HCC tumor assays","pmids":["33393494","34255829","33380426","34117217","33500384","33924599"],"confidence":"High","gaps":["Integration of competing localization/regulatory inputs not modeled","Several axes (TRAF2 vesicle, TROAP, CDK5) rest on single-lab evidence"]},{"year":2023,"claim":"Defined new kinase-independent and circuit-level roles — chromatin-accessibility-driven ACE2/DPP4 transcription enabling coronavirus entry, and an ABLIM3 synaptic substrate controlling feedforward inhibition and social behavior.","evidence":"Genome-wide CRISPR screen with kinase-dead rescue and ATAC-seq; genetic epistasis, chemogenetics, electrophysiology, and behavior in Dyrk1a+/- mice","pmids":["37310920","37797581"],"confidence":"High","gaps":["How DYRK1A promotes chromatin accessibility mechanistically unresolved","ABLIM3 phosphosite and direct kinase action not fully detailed"]},{"year":2023,"claim":"Implicated DYRK1A in Parkinson's-relevant alpha-synuclein Ser129 phosphorylation, though only via in vivo knockdown correlation.","evidence":"AAV-shRNA knockdown in a PD model with Western blot for P-alpha-synuclein and apoptosis markers","pmids":["37469393"],"confidence":"Low","gaps":["Direct in vitro phosphorylation of alpha-synuclein not demonstrated","Single study; correlation not causation"]},{"year":null,"claim":"How DYRK1A's many competing regulatory inputs (14-3-3, PPM1B, TRAF2 ubiquitination, TROAP, proteolysis) are integrated to direct it to specific substrates and subcellular compartments in a given cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model of localization/substrate selection","Kinase-dependent vs kinase-independent contributions not systematically partitioned across tissues"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,6,8,9,10,13,17,18,26]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,26]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,9,14,23]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[12]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,9,14,25]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[20,22]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[20]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[9,13]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[6,8,11,17]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,2,14,23]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[17,18]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[15,20,28]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[3,24]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[14,23]}],"complexes":["DREAM complex"],"partners":["LIN52","RCAN1","SIRT1","TRAF3","TRAF2","PPM1B","TROAP","EP300"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13627","full_name":"Dual specificity tyrosine-phosphorylation-regulated kinase 1A","aliases":["Dual specificity YAK1-related kinase","HP86","Protein kinase minibrain homolog","MNBH","hMNB"],"length_aa":763,"mass_kda":85.6,"function":"Dual-specificity kinase which possesses both serine/threonine and tyrosine kinase activities (PubMed:20981014, PubMed:21127067, PubMed:23665168, PubMed:30773093, PubMed:8769099). Exhibits a substrate preference for proline at position P+1 and arginine at position P-3 (PubMed:23665168). Plays an important role in double-strand breaks (DSBs) repair following DNA damage (PubMed:31024071). Mechanistically, phosphorylates RNF169 and increases its ability to block accumulation of TP53BP1 at the DSB sites thereby promoting homologous recombination repair (HRR) (PubMed:30773093). Also acts as a positive regulator of transcription by acting as a CTD kinase that mediates phosphorylation of the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAP II) POLR2A (PubMed:25620562, PubMed:29849146). May play a role in a signaling pathway regulating nuclear functions of cell proliferation (PubMed:14500717). Modulates alternative splicing by phosphorylating the splice factor SRSF6 (By similarity). Has pro-survival function and negatively regulates the apoptotic process (By similarity). Promotes cell survival upon genotoxic stress through phosphorylation of SIRT1 (By similarity). This in turn inhibits p53/TP53 activity and apoptosis (By similarity). Phosphorylates SEPTIN4, SEPTIN5 and SF3B1 at 'Thr-434' (By similarity)","subcellular_location":"Nucleus; Nucleus speckle","url":"https://www.uniprot.org/uniprotkb/Q13627/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/DYRK1A","classification":"Not Classified","n_dependent_lines":150,"n_total_lines":1208,"dependency_fraction":0.12417218543046357},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"DYNLL2","stoichiometry":4.0},{"gene":"FAM117B","stoichiometry":4.0},{"gene":"CLTA","stoichiometry":0.2},{"gene":"DYNLL1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/DYRK1A","total_profiled":1310},"omim":[{"mim_id":"619039","title":"REPLICATION INITIATOR 1; REPIN1","url":"https://www.omim.org/entry/619039"},{"mim_id":"614791","title":"MICRO RNA 199B; MIR199B","url":"https://www.omim.org/entry/614791"},{"mim_id":"614104","title":"INTELLECTUAL DEVELOPMENTAL DISORDER, AUTOSOMAL DOMINANT 7; MRD7","url":"https://www.omim.org/entry/614104"},{"mim_id":"613482","title":"CYCLIN L2; CCNL2","url":"https://www.omim.org/entry/613482"},{"mim_id":"610607","title":"CYTOPLASMIC POLYADENYLATION ELEMENT-BINDING PROTEIN 4; CPEB4","url":"https://www.omim.org/entry/610607"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nuclear speckles","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Centrosome","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/DYRK1A"},"hgnc":{"alias_symbol":[],"prev_symbol":["DYRK1","DYRK","MNBH"]},"alphafold":{"accession":"Q13627","domains":[{"cath_id":"3.30.200.20","chopping":"141-240","consensus_level":"medium","plddt":97.0756,"start":141,"end":240},{"cath_id":"1.10.510.10","chopping":"241-478","consensus_level":"high","plddt":95.9352,"start":241,"end":478}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13627","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13627-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13627-F1-predicted_aligned_error_v6.png","plddt_mean":66.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=DYRK1A","jax_strain_url":"https://www.jax.org/strain/search?query=DYRK1A"},"sequence":{"accession":"Q13627","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13627.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13627/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13627"}},"corpus_meta":[{"pmid":"12192061","id":"PMC_12192061","title":"Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12192061","citation_count":281,"is_preprint":false},{"pmid":"11311121","id":"PMC_11311121","title":"The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase.","date":"2001","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/11311121","citation_count":273,"is_preprint":false},{"pmid":"21048044","id":"PMC_21048044","title":"DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles.","date":"2010","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/21048044","citation_count":256,"is_preprint":false},{"pmid":"21498570","id":"PMC_21498570","title":"DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly.","date":"2011","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/21498570","citation_count":249,"is_preprint":false},{"pmid":"19474792","id":"PMC_19474792","title":"Polar gradients of the DYRK-family kinase Pom1 couple cell length with the cell cycle.","date":"2009","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/19474792","citation_count":243,"is_preprint":false},{"pmid":"21156028","id":"PMC_21156028","title":"The role of DYRK1A in neurodegenerative diseases.","date":"2010","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/21156028","citation_count":221,"is_preprint":false},{"pmid":"19796173","id":"PMC_19796173","title":"Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation.","date":"2009","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/19796173","citation_count":216,"is_preprint":false},{"pmid":"9932450","id":"PMC_9932450","title":"Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity.","date":"1999","source":"Progress in nucleic acid research and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9932450","citation_count":201,"is_preprint":false},{"pmid":"20167603","id":"PMC_20167603","title":"DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20167603","citation_count":193,"is_preprint":false},{"pmid":"21156027","id":"PMC_21156027","title":"MNB/DYRK1A as a multiple regulator of neuronal development.","date":"2010","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/21156027","citation_count":178,"is_preprint":false},{"pmid":"21126318","id":"PMC_21126318","title":"Activation, regulation, and inhibition of DYRK1A.","date":"2010","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/21126318","citation_count":171,"is_preprint":false},{"pmid":"26496802","id":"PMC_26496802","title":"Inhibition of DYRK1A and GSK3B induces human β-cell proliferation.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26496802","citation_count":170,"is_preprint":false},{"pmid":"19685005","id":"PMC_19685005","title":"Function and regulation of Dyrk1A: towards understanding Down syndrome.","date":"2009","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/19685005","citation_count":167,"is_preprint":false},{"pmid":"26953159","id":"PMC_26953159","title":"Inhibition of DYRK1A Stimulates Human β-Cell Proliferation.","date":"2016","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/26953159","citation_count":166,"is_preprint":false},{"pmid":"12138125","id":"PMC_12138125","title":"Regulation of Gli1 transcriptional activity in the nucleus by Dyrk1.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12138125","citation_count":155,"is_preprint":false},{"pmid":"10329007","id":"PMC_10329007","title":"Human minibrain homologue (MNBH/DYRK1): characterization, alternative splicing, differential tissue expression, and overexpression in Down syndrome.","date":"1999","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10329007","citation_count":147,"is_preprint":false},{"pmid":"11518709","id":"PMC_11518709","title":"Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11518709","citation_count":145,"is_preprint":false},{"pmid":"27375444","id":"PMC_27375444","title":"DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome.","date":"2016","source":"Frontiers in behavioral neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27375444","citation_count":144,"is_preprint":false},{"pmid":"25795597","id":"PMC_25795597","title":"DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications.","date":"2015","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25795597","citation_count":130,"is_preprint":false},{"pmid":"30268771","id":"PMC_30268771","title":"DYRK1A and cognition: A lifelong relationship.","date":"2018","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/30268771","citation_count":128,"is_preprint":false},{"pmid":"19081073","id":"PMC_19081073","title":"The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development.","date":"2008","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/19081073","citation_count":111,"is_preprint":false},{"pmid":"28779511","id":"PMC_28779511","title":"Dyrk1 inhibition improves Alzheimer's disease-like pathology.","date":"2017","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/28779511","citation_count":99,"is_preprint":false},{"pmid":"24801365","id":"PMC_24801365","title":"Excitation/inhibition balance and learning are modified by Dyrk1a gene dosage.","date":"2014","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/24801365","citation_count":98,"is_preprint":false},{"pmid":"29985601","id":"PMC_29985601","title":"Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.","date":"2018","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29985601","citation_count":97,"is_preprint":false},{"pmid":"27308401","id":"PMC_27308401","title":"DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis.","date":"2015","source":"Molecular & cellular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27308401","citation_count":92,"is_preprint":false},{"pmid":"16338136","id":"PMC_16338136","title":"The C. elegans DYRK Kinase MBK-2 Marks Oocyte Proteins for Degradation in Response to Meiotic Maturation.","date":"2005","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/16338136","citation_count":92,"is_preprint":false},{"pmid":"34954592","id":"PMC_34954592","title":"DYRK1A inhibitors for disease therapy: Current status and perspectives.","date":"2021","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34954592","citation_count":88,"is_preprint":false},{"pmid":"22918246","id":"PMC_22918246","title":"Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control.","date":"2012","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/22918246","citation_count":86,"is_preprint":false},{"pmid":"24152332","id":"PMC_24152332","title":"DYRK1A: a potential drug target for multiple Down syndrome neuropathologies.","date":"2014","source":"CNS & neurological disorders drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/24152332","citation_count":78,"is_preprint":false},{"pmid":"32751160","id":"PMC_32751160","title":"The DYRK Family of Kinases in Cancer: Molecular Functions and Therapeutic Opportunities.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32751160","citation_count":77,"is_preprint":false},{"pmid":"33393494","id":"PMC_33393494","title":"DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3.","date":"2021","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/33393494","citation_count":72,"is_preprint":false},{"pmid":"34445804","id":"PMC_34445804","title":"GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34445804","citation_count":71,"is_preprint":false},{"pmid":"21965663","id":"PMC_21965663","title":"Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21965663","citation_count":68,"is_preprint":false},{"pmid":"9918863","id":"PMC_9918863","title":"Cloning and characterization of DYRK1B, a novel member of the DYRK family of protein kinases.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9918863","citation_count":67,"is_preprint":false},{"pmid":"15068246","id":"PMC_15068246","title":"The MNB/DYRK1A protein kinase: genetic and biochemical properties.","date":"2003","source":"Journal of neural transmission. Supplementum","url":"https://pubmed.ncbi.nlm.nih.gov/15068246","citation_count":66,"is_preprint":false},{"pmid":"15068245","id":"PMC_15068245","title":"The MNB/DYRK1A protein kinase: neurobiological functions and Down syndrome implications.","date":"2003","source":"Journal of neural transmission. Supplementum","url":"https://pubmed.ncbi.nlm.nih.gov/15068245","citation_count":65,"is_preprint":false},{"pmid":"32870330","id":"PMC_32870330","title":"DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis.","date":"2020","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/32870330","citation_count":62,"is_preprint":false},{"pmid":"30332747","id":"PMC_30332747","title":"DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome.","date":"2018","source":"Brain sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30332747","citation_count":62,"is_preprint":false},{"pmid":"34828439","id":"PMC_34828439","title":"Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome.","date":"2021","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/34828439","citation_count":59,"is_preprint":false},{"pmid":"30343272","id":"PMC_30343272","title":"DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth.","date":"2018","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/30343272","citation_count":59,"is_preprint":false},{"pmid":"26079075","id":"PMC_26079075","title":"DYRK protein kinases.","date":"2015","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/26079075","citation_count":58,"is_preprint":false},{"pmid":"23016545","id":"PMC_23016545","title":"DYRK1A kinase inhibitors with emphasis on cancer.","date":"2012","source":"Mini reviews in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23016545","citation_count":57,"is_preprint":false},{"pmid":"27073990","id":"PMC_27073990","title":"DYRK1A inhibition as potential treatment for Alzheimer's disease.","date":"2016","source":"Future medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27073990","citation_count":57,"is_preprint":false},{"pmid":"36012629","id":"PMC_36012629","title":"The Omnipresence of DYRK1A in Human Diseases.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36012629","citation_count":56,"is_preprint":false},{"pmid":"29034068","id":"PMC_29034068","title":"Clinical phenotype of ASD-associated DYRK1A haploinsufficiency.","date":"2017","source":"Molecular autism","url":"https://pubmed.ncbi.nlm.nih.gov/29034068","citation_count":56,"is_preprint":false},{"pmid":"30059217","id":"PMC_30059217","title":"Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.","date":"2018","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30059217","citation_count":56,"is_preprint":false},{"pmid":"25998054","id":"PMC_25998054","title":"The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells.","date":"2015","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/25998054","citation_count":55,"is_preprint":false},{"pmid":"27056896","id":"PMC_27056896","title":"Dyrk1a regulates the cardiomyocyte cell cycle via D-cyclin-dependent Rb/E2f-signalling.","date":"2016","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/27056896","citation_count":54,"is_preprint":false},{"pmid":"28766366","id":"PMC_28766366","title":"Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.","date":"2017","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/28766366","citation_count":52,"is_preprint":false},{"pmid":"35220406","id":"PMC_35220406","title":"The chromosome 21 kinase DYRK1A: emerging roles in cancer biology and potential as a therapeutic target.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35220406","citation_count":51,"is_preprint":false},{"pmid":"26192590","id":"PMC_26192590","title":"Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26192590","citation_count":50,"is_preprint":false},{"pmid":"34344863","id":"PMC_34344863","title":"Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34344863","citation_count":49,"is_preprint":false},{"pmid":"33682417","id":"PMC_33682417","title":"DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes.","date":"2021","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33682417","citation_count":47,"is_preprint":false},{"pmid":"31821176","id":"PMC_31821176","title":"Pharmacologic and genetic approaches define human pancreatic β cell mitogenic targets of DYRK1A inhibitors.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31821176","citation_count":45,"is_preprint":false},{"pmid":"24870561","id":"PMC_24870561","title":"Dyrk1A induces pancreatic β cell mass expansion and improves glucose tolerance.","date":"2014","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/24870561","citation_count":44,"is_preprint":false},{"pmid":"34255829","id":"PMC_34255829","title":"DYRK1a mediates BAFF-induced noncanonical NF-κB activation to promote autoimmunity and B-cell leukemogenesis.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34255829","citation_count":43,"is_preprint":false},{"pmid":"29039762","id":"PMC_29039762","title":"Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases.","date":"2017","source":"Marine drugs","url":"https://pubmed.ncbi.nlm.nih.gov/29039762","citation_count":41,"is_preprint":false},{"pmid":"30243157","id":"PMC_30243157","title":"DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective.","date":"2018","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30243157","citation_count":40,"is_preprint":false},{"pmid":"29742440","id":"PMC_29742440","title":"DYRK1A Kinase Positively Regulates Angiogenic Responses in Endothelial Cells.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29742440","citation_count":40,"is_preprint":false},{"pmid":"28944229","id":"PMC_28944229","title":"Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits.","date":"2017","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28944229","citation_count":40,"is_preprint":false},{"pmid":"29223763","id":"PMC_29223763","title":"DYRK1A-haploinsufficiency in mice causes autistic-like features and febrile seizures.","date":"2017","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29223763","citation_count":40,"is_preprint":false},{"pmid":"30885273","id":"PMC_30885273","title":"Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice.","date":"2019","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/30885273","citation_count":40,"is_preprint":false},{"pmid":"9878567","id":"PMC_9878567","title":"Expression of the mnb (dyrk) protein in adult and embryonic mouse tissues.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9878567","citation_count":39,"is_preprint":false},{"pmid":"36876904","id":"PMC_36876904","title":"Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases.","date":"2023","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36876904","citation_count":37,"is_preprint":false},{"pmid":"15906374","id":"PMC_15906374","title":"Regulation of the proapoptotic activity of huntingtin interacting protein 1 by Dyrk1 and caspase-3 in hippocampal neuroprogenitor cells.","date":"2005","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/15906374","citation_count":37,"is_preprint":false},{"pmid":"31240602","id":"PMC_31240602","title":"Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice.","date":"2019","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/31240602","citation_count":35,"is_preprint":false},{"pmid":"9070862","id":"PMC_9070862","title":"The murine Dyrk protein maps to chromosome 16, localizes to the nucleus, and can form multimers.","date":"1997","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9070862","citation_count":33,"is_preprint":false},{"pmid":"27567487","id":"PMC_27567487","title":"Understanding the Multifaceted Role of Human Down Syndrome Kinase DYRK1A.","date":"2016","source":"Advances in protein chemistry and structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/27567487","citation_count":32,"is_preprint":false},{"pmid":"30137413","id":"PMC_30137413","title":"DYRK1A interacts with histone acetyl transferase p300 and CBP and localizes to enhancers.","date":"2018","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/30137413","citation_count":32,"is_preprint":false},{"pmid":"15369779","id":"PMC_15369779","title":"Regulation of Dyrk1A kinase activity by 14-3-3.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15369779","citation_count":32,"is_preprint":false},{"pmid":"33500384","id":"PMC_33500384","title":"TROAP switches DYRK1 activity to drive hepatocellular carcinoma progression.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33500384","citation_count":31,"is_preprint":false},{"pmid":"36990324","id":"PMC_36990324","title":"Function and inhibition of DYRK1A: Emerging roles of treating multiple human diseases.","date":"2023","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36990324","citation_count":30,"is_preprint":false},{"pmid":"23948904","id":"PMC_23948904","title":"Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) enhances tau expression.","date":"2013","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/23948904","citation_count":30,"is_preprint":false},{"pmid":"22359282","id":"PMC_22359282","title":"Dyrk kinases regulate phosphorylation of doublecortin, cytoskeletal organization, and neuronal morphology.","date":"2012","source":"Cytoskeleton (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/22359282","citation_count":30,"is_preprint":false},{"pmid":"29615569","id":"PMC_29615569","title":"Emerging Roles of DYRK Kinases in Embryogenesis and Hedgehog Pathway Control.","date":"2017","source":"Journal of developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/29615569","citation_count":29,"is_preprint":false},{"pmid":"35369706","id":"PMC_35369706","title":"Inhibition of DYRK1a Enhances Cardiomyocyte Cycling After Myocardial Infarction.","date":"2022","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/35369706","citation_count":28,"is_preprint":false},{"pmid":"35194165","id":"PMC_35194165","title":"APP and DYRK1A regulate axonal and synaptic vesicle protein networks and mediate Alzheimer's pathology in trisomy 21 neurons.","date":"2022","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/35194165","citation_count":28,"is_preprint":false},{"pmid":"32896600","id":"PMC_32896600","title":"The novel DYRK1A inhibitor KVN93 regulates cognitive function, amyloid-beta pathology, and neuroinflammation.","date":"2020","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32896600","citation_count":28,"is_preprint":false},{"pmid":"32213288","id":"PMC_32213288","title":"An atypical DYRK kinase connects quorum-sensing with posttranscriptional gene regulation in Trypanosoma brucei.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/32213288","citation_count":26,"is_preprint":false},{"pmid":"29364148","id":"PMC_29364148","title":"Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design.","date":"2018","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/29364148","citation_count":26,"is_preprint":false},{"pmid":"33975430","id":"PMC_33975430","title":"Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors.","date":"2021","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33975430","citation_count":25,"is_preprint":false},{"pmid":"37396550","id":"PMC_37396550","title":"New insights into the roles for DYRK family in mammalian development and congenital diseases.","date":"2022","source":"Genes & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/37396550","citation_count":24,"is_preprint":false},{"pmid":"26145823","id":"PMC_26145823","title":"Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis.","date":"2015","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26145823","citation_count":24,"is_preprint":false},{"pmid":"37487467","id":"PMC_37487467","title":"Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B.","date":"2023","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37487467","citation_count":23,"is_preprint":false},{"pmid":"37310920","id":"PMC_37310920","title":"DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner.","date":"2023","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/37310920","citation_count":23,"is_preprint":false},{"pmid":"22110360","id":"PMC_22110360","title":"Dyrk1A Positively Stimulates ASK1-JNK Signaling Pathway during Apoptotic Cell Death.","date":"2011","source":"Experimental neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/22110360","citation_count":22,"is_preprint":false},{"pmid":"37435081","id":"PMC_37435081","title":"Lomerizine inhibits LPS-mediated neuroinflammation and tau hyperphosphorylation by modulating NLRP3, DYRK1A, and GSK3α/β.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37435081","citation_count":21,"is_preprint":false},{"pmid":"33380426","id":"PMC_33380426","title":"Protein phosphatase PPM1B inhibits DYRK1A kinase through dephosphorylation of pS258 and reduces toxic tau aggregation.","date":"2021","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33380426","citation_count":21,"is_preprint":false},{"pmid":"34571911","id":"PMC_34571911","title":"DYRK1A Kinase Inhibitors Promote β-Cell Survival and Insulin Homeostasis.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34571911","citation_count":20,"is_preprint":false},{"pmid":"32101481","id":"PMC_32101481","title":"DYRK kinase Pom1 drives F-BAR protein Cdc15 from the membrane to promote medial division.","date":"2020","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/32101481","citation_count":20,"is_preprint":false},{"pmid":"33924599","id":"PMC_33924599","title":"DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33924599","citation_count":20,"is_preprint":false},{"pmid":"37797581","id":"PMC_37797581","title":"An inhibitory circuit-based enhancer of DYRK1A function reverses Dyrk1a-associated impairment in social recognition.","date":"2023","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/37797581","citation_count":19,"is_preprint":false},{"pmid":"35726411","id":"PMC_35726411","title":"DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease.","date":"2023","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35726411","citation_count":18,"is_preprint":false},{"pmid":"34117217","id":"PMC_34117217","title":"K63-linked ubiquitination of DYRK1A by TRAF2 alleviates Sprouty 2-mediated degradation of EGFR.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34117217","citation_count":18,"is_preprint":false},{"pmid":"38862481","id":"PMC_38862481","title":"Functional analysis of the Aspergillus fumigatus kinome identifies a druggable DYRK kinase that regulates septal plugging.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38862481","citation_count":17,"is_preprint":false},{"pmid":"37900285","id":"PMC_37900285","title":"Insights from the protein interaction Universe of the multifunctional \"Goldilocks\" kinase DYRK1A.","date":"2023","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/37900285","citation_count":17,"is_preprint":false},{"pmid":"32587776","id":"PMC_32587776","title":"DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors.","date":"2020","source":"Cancer biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32587776","citation_count":17,"is_preprint":false},{"pmid":"36651299","id":"PMC_36651299","title":"Resveratrol induces DNA damage-mediated cancer cell senescence through the DLC1-DYRK1A-EGFR axis.","date":"2023","source":"Food & function","url":"https://pubmed.ncbi.nlm.nih.gov/36651299","citation_count":16,"is_preprint":false},{"pmid":"25768698","id":"PMC_25768698","title":"Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.","date":"2015","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25768698","citation_count":16,"is_preprint":false},{"pmid":"37469393","id":"PMC_37469393","title":"Dyrk1a Phosphorylation of α-Synuclein Mediating Apoptosis of Dopaminergic Neurons in Parkinson's Disease.","date":"2023","source":"Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/37469393","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45048,"output_tokens":7376,"usd":0.122892,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16590,"output_tokens":5884,"usd":0.115025,"stage2_stop_reason":"end_turn"},"total_usd":0.237917,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"DYRK1A (and DYRK2) phosphorylates eIF2Bepsilon at Ser539 in vitro, priming it for subsequent GSK3 phosphorylation at Ser535; DYRK1A also phosphorylates tau at Thr212 in vitro, priming tau for GSK3 phosphorylation at Ser208, establishing DYRK1A as a GSK3-priming kinase.\",\n      \"method\": \"In vitro kinase assays with recombinant proteins; comparison across multiple proline-directed kinases; in vivo phosphorylation state analysis\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with multiple substrates and kinase comparisons, combined with in vivo validation of Ser539 phosphorylation state\",\n      \"pmids\": [\"11311121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"DYRK1A directly phosphorylates CREB during neuronal differentiation of hippocampal progenitor cells, leading to stimulation of CRE-mediated gene transcription; DYRK1A activity is induced by bFGF and specifically binds active CREB.\",\n      \"method\": \"In vitro kinase assay; co-immunoprecipitation; reporter gene assay; dominant-negative blockade of DYRK1A in H19-7 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct phosphorylation demonstrated in vitro plus cellular functional readout (neurite outgrowth, CREB phosphorylation), single lab\",\n      \"pmids\": [\"11518709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"DYRK1A (Dyrk1) enhances Gli1-dependent transcriptional activity in the nucleus by retaining Gli1 in the nucleus and increasing its transcriptional activity independently of nuclear export; DYRK1A acts synergistically with Sonic hedgehog signaling but is not regulated by Shh.\",\n      \"method\": \"Reporter gene assays; nuclear localization assays; co-expression studies in C3H10T1/2 cells; kinase activity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cellular assays showing nuclear retention and transcriptional enhancement, single lab\",\n      \"pmids\": [\"12138125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Dyrk1A haploinsufficiency in mice causes decreased brain size, increased neuronal densities in specific regions, reduced neuron numbers in superior colliculus, and neonatal lethality of nulls at midgestation, establishing a nonredundant vital role in brain growth.\",\n      \"method\": \"Gene targeting (knockout mouse); cell counting; histological analysis; neurobehavioral testing\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function with specific quantitative phenotypic readouts in vivo, well-replicated model\",\n      \"pmids\": [\"12192061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"14-3-3 protein interacts with the N-terminus of DYRK1A independently of DYRK1A phosphorylation status, and this binding increases DYRK1A kinase activity in a dose-dependent manner in vitro; a peptide inhibiting 14-3-3 binding decreased DYRK1A activity in COS7 cells.\",\n      \"method\": \"Yeast two-hybrid screen; in vitro binding assay; in vitro kinase assay; co-immunoprecipitation; cell-based kinase assay with inhibitory peptide\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal binding confirmed in vitro and in vivo, functional kinase modulation demonstrated, single lab\",\n      \"pmids\": [\"15369779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"DYRK1A selectively binds and phosphorylates HIP-1 (huntingtin-interacting protein 1) during neuronal differentiation; DYRK1A-mediated phosphorylation of HIP-1 blocks HIP-1-mediated cell death and enhances neurite outgrowth; upon apoptotic stimulation (etoposide), HIP-1 dissociates from DYRK1A and binds caspase-3, promoting its activation.\",\n      \"method\": \"Co-immunoprecipitation; in vitro kinase assay; cell death assays; neurite outgrowth measurement in H19-7 cells\",\n      \"journal\": \"Journal of neuroscience research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct phosphorylation demonstrated in vitro, binding and functional consequences shown in cells, single lab\",\n      \"pmids\": [\"15906374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"DYRK1A phosphorylates caspase-9 on threonine residue 125, and this phosphorylation event is required to protect retina cells from apoptotic cell death during development; changes in Dyrk1a gene dosage strongly alter inner retina layer cellularity without affecting proliferation or specification of progenitors.\",\n      \"method\": \"In vitro kinase assay; gene dosage manipulation (knockout/overexpression mice); retinal cell counting; functional electroretinography\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct phosphorylation site identified in vitro with in vivo genetic dosage validation and functional phenotypic readouts\",\n      \"pmids\": [\"19081073\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Harmine is a potent and selective inhibitor of DYRK1A (IC50 ~33 nM for substrate phosphorylation in vitro), inhibiting DYRK1A more potently than DYRK1B, DYRK2, or DYRK4; harmine inhibits DYRK1A substrate phosphorylation in cultured cells (IC50 ~48 nM) and interferes with neuritogenesis in hippocampal neurons.\",\n      \"method\": \"In vitro kinase assay; in vitro bacterial translation system; cell-based substrate phosphorylation assay; hippocampal neuron culture with neurite analysis\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — quantitative in vitro and cellular assays with multiple substrates and kinase family members compared, replicated by multiple subsequent studies\",\n      \"pmids\": [\"19796173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"DYRK1A directly phosphorylates SIRT1 at Thr522, activating its deacetylase activity by promoting product release and increasing enzymatic turnover; activated SIRT1 deacetylates p53, promoting cell survival; knockdown of DYRK1A leads to hypophosphorylation of SIRT1 and sensitizes cells to DNA damage-induced death.\",\n      \"method\": \"In vitro kinase assay; phosphomimetic/dephosphorylation mimetic mutants; deacetylase activity assays; siRNA knockdown; apoptosis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with phosphosite mutagenesis and enzymatic activity readout; multiple orthogonal assays in one study\",\n      \"pmids\": [\"20167603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"DYRK1A specifically phosphorylates LIN52 on serine residue 28, and this phosphorylation is required for DREAM complex assembly (containing p130, E2F4, DP1, and MuvB core proteins); inhibiting DYRK1A activity or mutating LIN52 S28 disrupts DREAM assembly and impairs entry into quiescence and Ras-induced senescence.\",\n      \"method\": \"Mass spectrometric phosphopeptide identification; in vitro kinase assay with point mutants; co-immunoprecipitation of DREAM components; quiescence and senescence assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — phosphosite identified by MS and confirmed by in vitro kinase assay with mutagenesis, functional consequence validated in multiple cellular contexts\",\n      \"pmids\": [\"21498570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"DYRK1A directly interacts with and phosphorylates RCAN1 at Ser112 and Thr192; phosphorylation at Ser112 primes RCAN1 for GSK3β phosphorylation at Ser108; phosphorylation at Thr192 enhances RCAN1 inhibition of calcineurin phosphatase activity, reduces NFAT transcriptional activity, extends RCAN1 half-life, and enhances tau phosphorylation.\",\n      \"method\": \"Co-immunoprecipitation; in vitro kinase assay; calcineurin phosphatase activity assay; NFAT reporter assay; protein half-life measurement; immunohistochemistry in transgenic mice\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct phosphorylation at two sites demonstrated in vitro, functional consequences of each site validated in cells and in transgenic mice\",\n      \"pmids\": [\"21965663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"DYRK1A positively regulates the ASK1-JNK signaling pathway during apoptotic cell death; DYRK1A directly interacts with and phosphorylates ASK1, promoting ASK1-mediated JNK1 activation.\",\n      \"method\": \"Co-immunoprecipitation; in vitro kinase assay; JNK activity assay; apoptosis induction in neuronal cells\",\n      \"journal\": \"Experimental neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct interaction and phosphorylation shown in vitro plus functional pathway activation in cells, single lab\",\n      \"pmids\": [\"22110360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"DYRK1A enhances tau mRNA stability (not transcription) to increase tau expression in a dose-dependent, kinase-activity-independent manner, preferentially increasing exon 10-containing isoforms.\",\n      \"method\": \"RT-PCR and Western blot for tau mRNA/protein; co-expression in HEK-293FT cells; kinase-dead mutant; mRNA stability assay; analysis of Ts65Dn mouse brains\",\n      \"journal\": \"Journal of Alzheimer's disease : JAD\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinase-dead mutant distinguishes kinase-independent mechanism; mRNA stability measured directly; confirmed in vivo in trisomy mice\",\n      \"pmids\": [\"23948904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"DYRK1A interacts with all members of the D-cyclin family and represses their protein levels; specifically, forced DYRK1A expression increases phosphorylation of Cyclin D2 (Ccnd2) at Thr280, promoting its proteasomal degradation; this results in hypo-phosphorylated Rb1, suppressed Rb/E2F signaling, and impaired cardiomyocyte cell cycle progression.\",\n      \"method\": \"Transgenic cardiac-specific overexpression mouse; co-immunoprecipitation; in vitro kinase assay; Western blot for cyclin levels; proteasome inhibitor rescue; E2F target gene expression analysis\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — phosphorylation site identified (Thr280), proteasomal degradation confirmed, downstream Rb/E2F signaling pathway characterized in vivo transgenic model\",\n      \"pmids\": [\"27056896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DYRK1A interacts with histone acetyltransferases p300 and CBP; overexpression of DYRK1A causes hyperphosphorylation of p300 and CBP; DYRK1A co-localizes genome-wide with p300 and CBP at enhancers and near transcription start sites; DYRK1A knockdown reduces H3K27 acetylation at enhancers, indicating DYRK1A modulates p300/CBP activity at enhancers.\",\n      \"method\": \"Proteomics/mass spectrometry; co-immunoprecipitation; ChIP-sequencing; shRNA knockdown and overexpression; H3K27ac ChIP-seq\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods (proteomics, reciprocal Co-IP, genome-wide ChIP-seq, functional KD), single lab\",\n      \"pmids\": [\"30137413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DYRK1A positively regulates VEGF-dependent NFAT transcriptional responses in endothelial cells by maintaining VEGFR2 accumulation; DYRK1A silencing reduces intracellular Ca2+ influx in response to VEGF, dampening PLCγ1 activation and NFAT signaling; Dyrk1a heterozygous mice show defects in developmental retinal vascularization.\",\n      \"method\": \"siRNA silencing in primary endothelial cells; Ca2+ imaging; NFAT reporter assay; VEGFR2 accumulation assay; PLCγ1 phosphorylation; retinal vascularization in heterozygous mice\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal cellular assays plus in vivo genetic validation in heterozygous mice\",\n      \"pmids\": [\"29742440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DYRK1A undergoes proteolytic processing in Alzheimer's disease patient hippocampus; truncated forms accumulate in astrocytes and exhibit increased affinity towards STAT3α; proteolysis modifies DYRK1A kinase substrate specificity without abolishing kinase activity.\",\n      \"method\": \"Western blot of human AD and control hippocampus; immunohistochemistry; in vitro proteolysis assay; substrate affinity comparison; APP/PS1 mouse model analysis\",\n      \"journal\": \"Acta neuropathologica communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic finding in human tissue confirmed in mouse model with biochemical substrate specificity characterization, single lab\",\n      \"pmids\": [\"30885273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"DYRK1A phosphorylates FOXO1 and STAT3 to support B-ALL development; genetic and pharmacological inhibition of DYRK1A decreases leukemic cell expansion; loss of DYRK1A-mediated FOXO1/STAT3 signaling disrupts DNA damage and ROS regulation, leading to preferential cell death in leukemic B cells.\",\n      \"method\": \"Genetic knockdown and pharmacological inhibition; in vitro and in vivo leukemia models; substrate phosphorylation assays; ROS and DNA damage assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct substrate identification with genetic and pharmacological validation in vitro and in vivo, multiple orthogonal methods\",\n      \"pmids\": [\"33393494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"DYRK1A phosphorylates TRAF3 at serine-29 to interfere with TRAF3-mediated NIK (NF-κB-inducing kinase) degradation, thereby facilitating BAFF-induced NIK accumulation and noncanonical NF-κB activation in B cells.\",\n      \"method\": \"Co-immunoprecipitation; in vitro kinase assay; genetic knockdown/knockout; noncanonical NF-κB pathway activation assays; mouse model of lupus and B-ALL\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — phosphosite identified (S29), mechanistic pathway established from substrate phosphorylation to NIK accumulation and NF-κB activation, validated in vivo\",\n      \"pmids\": [\"34255829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PPM1B (a PP2C family Ser/Thr phosphatase) dephosphorylates DYRK1A at Ser258, inhibiting DYRK1A activity; DYRK1A autophosphorylates Ser258; PPM1B-mediated dephosphorylation reduces DYRK1A-dependent tau phosphorylation at Thr212 and inhibits toxic tau oligomerization.\",\n      \"method\": \"LC-MS/MS identification of DYRK1A-binding proteins; in vitro kinase/phosphatase assays; co-immunoprecipitation; tau phosphorylation and aggregation assays in HEK293 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — autophosphorylation site and phosphatase identified biochemically, functional consequence on downstream substrate (tau) demonstrated with mechanistic clarity\",\n      \"pmids\": [\"33380426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRAF2 (E3 ligase) binds the PVQE motif of DYRK1A (between PEST and histidine repeat domain) and mediates K63-linked ubiquitination of DYRK1A, causing its translocation to vesicle membranes; vesicle-localized DYRK1A phosphorylates Sprouty 2, inhibiting EGFR degradation.\",\n      \"method\": \"Co-immunoprecipitation; ubiquitination assays (K63-linkage specific); subcellular fractionation; vesicle localization studies; EGFR degradation assays; DYRK1A knockdown\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — K63 ubiquitination and vesicle translocation demonstrated biochemically; functional downstream consequence shown; single lab\",\n      \"pmids\": [\"34117217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"DYRK1A promotes DYRK1A-CDK5-SOX2 axis in glioblastoma: DYRK1A deactivates CDK5 to decrease SOX2 expression and promote GSC differentiation commitment; DYRK1A inhibition insulates GSCs from differentiation signals by maintaining CDK5/SOX2 activity.\",\n      \"method\": \"siRNA knockdown; pharmacological inhibition; CDK5 activity assays; SOX2 expression analysis; glioblastoma stem cell self-renewal assays\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — pathway placed by genetic manipulation and kinase inhibition in cell lines, CDK5 as intermediary inferred from activity assays, single lab\",\n      \"pmids\": [\"33924599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TROAP directly binds DYRK1A/B and causes cytoplasmic retention of DYRK1A/B, promoting cell cycle progression via activation of Akt/GSK-3β signaling in hepatocellular carcinoma cells.\",\n      \"method\": \"Co-immunoprecipitation; subcellular fractionation/localization assays; shRNA knockdown; Akt/GSK-3β pathway activation assays; in vitro and in vivo tumor growth assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding and relocalization shown biochemically with functional consequence in cells and in vivo, single lab\",\n      \"pmids\": [\"33500384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"DYRK1A promotes viral entry of SARS-CoV, SARS-CoV-2, and MERS-CoV in a kinase-independent manner by regulating ACE2 and DPP4 transcription; DYRK1A promotes DNA accessibility at the ACE2 promoter and a putative distal enhancer.\",\n      \"method\": \"Genome-wide CRISPR/Cas9 screen; kinase-dead mutant rescue; ATAC-seq for chromatin accessibility; ACE2/DPP4 expression assays; viral entry assays in human and non-human primate cells\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — kinase-dead mutant establishes kinase-independent mechanism; ATAC-seq provides mechanistic basis; validated across species\",\n      \"pmids\": [\"37310920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"DYRK1A identifies ABLIM3 (a cytoskeletal protein) as a synaptic substrate in hippocampal mossy fiber-PV interneuron synapses; DYRK1A recruits feedforward inhibition of CA3 and CA2 via PV interneurons to promote social recognition; Ablim3 downregulation rescues PV IN-mediated inhibition and social behavior in Dyrk1a heterozygous mice.\",\n      \"method\": \"Genetic epistasis; viral knockdown of Ablim3 in dentate granule cells; chemogenetic activation of PV INs; electrophysiology; behavioral assays in Dyrk1a+/- mice\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis identifies ABLIM3 as substrate; circuit-level mechanism established with multiple orthogonal approaches (chemogenetics, genetics, behavior)\",\n      \"pmids\": [\"37797581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The murine Dyrk protein localizes to the cell nucleus, can self-associate (via leucine zipper), and maps to distal chromosome 16 (syntenic with human 21q22.2).\",\n      \"method\": \"Two-hybrid self-interaction assay; subcellular fractionation/immunostaining; chromosomal mapping by interspecific backcross\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct nuclear localization by fractionation; self-association confirmed in two-hybrid; foundational characterization paper\",\n      \"pmids\": [\"9070862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"DYRK1A is activated by tyrosine autophosphorylation in the activation loop (between subdomains VII and VIII) and subsequently phosphorylates exogenous substrates exclusively on serine/threonine residues; this dual-specificity mechanism is a defining biochemical property of the DYRK family.\",\n      \"method\": \"In vitro kinase assay; autophosphorylation analysis; substrate specificity profiling\",\n      \"journal\": \"Progress in nucleic acid research and molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical mechanism replicated across multiple labs and confirmed by subsequent structural and mutagenesis studies\",\n      \"pmids\": [\"9932450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DYRK1A phosphorylates α-synuclein at serine 129 (Ser129), and Dyrk1a knockdown reduces P-α-synuclein (Ser129) levels and activates the PI3K/AKT pathway, reducing dopaminergic neuron apoptosis in a Parkinson's disease model.\",\n      \"method\": \"AAV-shRNA knockdown of Dyrk1a in vivo; Western blot for P-α-synuclein Ser129; apoptosis markers; transcriptome and metabolome sequencing\",\n      \"journal\": \"Parkinson's disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — in vivo knockdown shows correlation between Dyrk1a levels and α-synuclein phosphorylation but direct in vitro phosphorylation not demonstrated in this abstract; single study\",\n      \"pmids\": [\"37469393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DYRK1A stabilizes the c-MET receptor through SPRY2, leading to prolonged activation of ERK signaling in pancreatic ductal adenocarcinoma; DYRK1A protein level positively correlates with c-MET levels.\",\n      \"method\": \"Knockdown experiments in PDAC cell lines; DYRK1A genetic reduction in mouse PDAC models; co-expression and protein stability analysis; ERK signaling measurement\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanism defined through genetic knockdown in vitro and in vivo, SPRY2-mediated pathway established, single lab\",\n      \"pmids\": [\"30343272\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"DYRK1A is a dual-specificity kinase that undergoes obligatory cotranslational tyrosine autophosphorylation in its activation loop to achieve full activity, after which it phosphorylates substrates exclusively on serine/threonine residues; it functions as a priming kinase for GSK3 on multiple substrates (eIF2Bε, tau, RCAN1), directly phosphorylates transcriptional regulators (CREB, Gli1, LIN52, FOXO1, STAT3), cell cycle proteins (caspase-9, Cyclin D2), survival factors (SIRT1, HIP-1, ASK1), and signaling pathway components (TRAF3, SPRY2), and its activity is regulated by 14-3-3 binding (activation), PPM1B-mediated dephosphorylation at Ser258 (inhibition), TRAF2-mediated K63-ubiquitination (vesicle translocation), and TROAP interaction (cytoplasmic retention); nuclear DYRK1A regulates DREAM complex assembly, enhancer activity via p300/CBP phosphorylation, and ACE2/DPP4 transcription in a kinase-independent manner, collectively establishing DYRK1A as a pleiotropic regulator of neuronal development, cell cycle, apoptosis, immunity, and angiogenesis whose gene dosage is critical in Down syndrome and related neurodevelopmental disorders.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"DYRK1A is a dual-specificity protein kinase that serves as a pleiotropic regulator of neuronal development, cell cycle progression, apoptosis, immunity, and angiogenesis, with its gene dosage critically constrained in brain development [#3, #26]. It achieves activity through tyrosine autophosphorylation in its activation loop and thereafter phosphorylates exogenous substrates exclusively on serine/threonine residues [#26]. A recurring biochemical theme is its action as a priming kinase that creates GSK3 phosphorylation sites, demonstrated for eIF2Bepsilon, tau, and RCAN1 [#0, #10]. Through direct substrate phosphorylation DYRK1A controls transcriptional programs (CREB, Gli1, the DREAM-complex subunit LIN52, FOXO1, STAT3) and couples to cell-cycle and survival machinery: it phosphorylates LIN52 at Ser28 to enable DREAM complex assembly and entry into quiescence/senescence [#9], phosphorylates caspase-9 at Thr125 and SIRT1 at Thr522 to favor cell survival [#6, #8], and represses D-cyclins by phosphorylating Cyclin D2 (Thr280) to drive its degradation and suppress Rb/E2F signaling [#13]. In the immune compartment it sustains B-lineage malignancy via FOXO1/STAT3 phosphorylation and activates noncanonical NF-kappaB by phosphorylating TRAF3 at Ser29 to block NIK degradation [#17, #18]. DYRK1A activity and localization are tuned by multiple inputs: 14-3-3 binding enhances activity, PPM1B dephosphorylates the autophosphorylation site Ser258 to inhibit it, TRAF2-mediated K63 ubiquitination relocalizes it to vesicles, and TROAP enforces cytoplasmic retention [#4, #19, #20, #22]. In addition to its catalytic roles, DYRK1A exerts kinase-independent functions, stabilizing tau mRNA and promoting chromatin accessibility at the ACE2/DPP4 loci to enable coronavirus entry [#12, #23], and it modulates enhancer activity through phosphorylation of the acetyltransferases p300/CBP [#14]. Several findings tie DYRK1A to neurological disease: it primes tau phosphorylation relevant to Alzheimer pathology and undergoes proteolytic processing in AD hippocampus that retunes its substrate specificity toward STAT3alpha [#0, #16, #19].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established the basic cell biology of the protein — where it acts and that it oligomerizes — placing it on the Down syndrome critical region of chromosome 21.\",\n      \"evidence\": \"Subcellular fractionation, two-hybrid self-interaction, and interspecific backcross mapping of murine Dyrk\",\n      \"pmids\": [\"9070862\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No catalytic activity or substrate defined\", \"Functional consequence of self-association unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defined the defining catalytic mechanism — resolving how a kinase with tyrosine autophosphorylation acts only as a Ser/Thr kinase on substrates.\",\n      \"evidence\": \"In vitro kinase assays with autophosphorylation analysis and substrate specificity profiling\",\n      \"pmids\": [\"9932450\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cotranslational nature of autophosphorylation not addressed here\", \"No physiological substrates identified at this stage\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified DYRK1A as a GSK3-priming kinase and a direct activator of CRE-dependent transcription, linking it to both tau biology and neuronal differentiation.\",\n      \"evidence\": \"In vitro kinase assays on eIF2Bepsilon/tau with cross-kinase comparison; Co-IP, reporter assays, and dominant-negative blockade in hippocampal progenitor cells\",\n      \"pmids\": [\"11311121\", \"11518709\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CREB phosphorylation site and selectivity defined by single lab\", \"Relative in vivo contribution of priming vs direct phosphorylation unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Genetic loss-of-function and a transcriptional readout together established a nonredundant, dosage-sensitive role in brain growth and Gli1-dependent transcription.\",\n      \"evidence\": \"Dyrk1A knockout mouse with histology and cell counting; reporter and nuclear localization assays in C3H10T1/2 cells\",\n      \"pmids\": [\"12192061\", \"12138125\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular substrates driving the brain phenotype not identified\", \"Mechanism of Gli1 nuclear retention not biochemically resolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed DYRK1A activity is regulated post-translationally by a protein interaction, revealing 14-3-3 as a positive modulator independent of phosphorylation status.\",\n      \"evidence\": \"Yeast two-hybrid, in vitro binding/kinase assays, and inhibitory-peptide cell assay\",\n      \"pmids\": [\"15369779\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of activation unknown\", \"Physiological contexts where 14-3-3 regulation operates not defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Extended DYRK1A into apoptotic control of neuronal differentiation by identifying HIP-1 as a substrate whose phosphorylation suppresses cell death.\",\n      \"evidence\": \"Co-IP, in vitro kinase assay, cell-death and neurite outgrowth assays in H19-7 cells\",\n      \"pmids\": [\"15906374\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Phosphosite on HIP-1 not mapped\", \"Single-lab cellular evidence\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Connected DYRK1A directly to apoptotic machinery in vivo by identifying caspase-9 Thr125 phosphorylation as dosage-sensitive protection of developing retina.\",\n      \"evidence\": \"In vitro kinase assay with site identification plus knockout/overexpression mice and electroretinography\",\n      \"pmids\": [\"19081073\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality beyond retina untested\", \"Interplay with other caspase-9 regulators not addressed\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Provided a selective chemical-genetic tool (harmine) enabling pharmacological dissection of DYRK1A in cells and neurons.\",\n      \"evidence\": \"Quantitative in vitro kinase assays across DYRK family, cell-based substrate assays, and hippocampal neuron neuritogenesis\",\n      \"pmids\": [\"19796173\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Off-target activity of harmine on other kinases\", \"Does not distinguish kinase-dependent from kinase-independent functions\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined a survival axis whereby DYRK1A phosphorylates SIRT1 (Thr522) to enhance its deacetylase turnover and p53 deacetylation, protecting cells from DNA-damage death.\",\n      \"evidence\": \"In vitro kinase assays, phosphosite mutants, deacetylase activity assays, siRNA knockdown, apoptosis assays\",\n      \"pmids\": [\"20167603\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of SIRT1 axis not tested\", \"Single-study mechanism\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established DYRK1A as a cell-cycle controller and broadened its priming-kinase and apoptotic roles by identifying LIN52 (DREAM assembly), RCAN1, and ASK1 as substrates.\",\n      \"evidence\": \"MS phosphosite mapping plus in vitro kinase assays with mutagenesis; DREAM Co-IP and quiescence/senescence assays; calcineurin and NFAT assays; JNK pathway assays\",\n      \"pmids\": [\"21498570\", \"21965663\", \"22110360\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How DYRK1A access to nuclear vs cytoplasmic substrates is controlled\", \"ASK1 finding rests on single-lab cellular evidence\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed a kinase-independent function — stabilization of tau mRNA favoring exon-10 isoforms — distinguishing DYRK1A's catalytic from non-catalytic contributions to tau pathology.\",\n      \"evidence\": \"Kinase-dead mutant, mRNA stability assays in HEK-293FT, and analysis of Ts65Dn mouse brain\",\n      \"pmids\": [\"23948904\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"RNA-binding mechanism unknown\", \"Whether DYRK1A binds tau mRNA directly not shown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed DYRK1A restrains the cell cycle by phosphorylating Cyclin D2 (Thr280) for degradation and suppressing Rb/E2F, explaining impaired cardiomyocyte proliferation.\",\n      \"evidence\": \"Cardiac-specific overexpression mice, Co-IP, in vitro kinase assay, proteasome rescue, E2F target analysis\",\n      \"pmids\": [\"27056896\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous-dosage relevance vs overexpression unclear\", \"Specificity among D-cyclins partially resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Expanded DYRK1A into chromatin/enhancer regulation and angiogenesis via p300/CBP phosphorylation and VEGFR2-dependent NFAT signaling.\",\n      \"evidence\": \"Proteomics, reciprocal Co-IP, ChIP-seq and H3K27ac ChIP-seq with knockdown; endothelial Ca2+ imaging, NFAT reporters, and heterozygous-mouse retinal vascularization\",\n      \"pmids\": [\"30137413\", \"29742440\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct p300/CBP phosphosites and functional consequences not fully mapped\", \"Mechanism of VEGFR2 maintenance not at molecular resolution\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked DYRK1A to oncogenic receptor signaling in solid tumors by stabilizing c-MET through SPRY2 and prolonging ERK activation.\",\n      \"evidence\": \"Knockdown in PDAC cell lines and mouse models with protein stability and ERK signaling analysis\",\n      \"pmids\": [\"30343272\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct phosphorylation events in the SPRY2/c-MET axis not defined here\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated that disease-associated proteolytic processing of DYRK1A retunes substrate specificity, accumulating in AD astrocytes with enhanced STAT3alpha affinity.\",\n      \"evidence\": \"Western blot/IHC of human AD hippocampus, in vitro proteolysis, substrate affinity comparison, APP/PS1 mouse analysis\",\n      \"pmids\": [\"30885273\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Protease responsible not identified\", \"Functional output of STAT3alpha rewiring in vivo unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A burst of studies defined DYRK1A's immune/oncogenic substrates (FOXO1/STAT3, TRAF3-Ser29) and a regulatory network (PPM1B dephosphorylation of Ser258, TRAF2 K63-ubiquitination/vesicle targeting, TROAP cytoplasmic retention, CDK5-SOX2 axis).\",\n      \"evidence\": \"Genetic/pharmacological leukemia models; Co-IP and in vitro kinase/phosphatase/ubiquitination assays; subcellular fractionation; GSC self-renewal and HCC tumor assays\",\n      \"pmids\": [\"33393494\", \"34255829\", \"33380426\", \"34117217\", \"33500384\", \"33924599\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Integration of competing localization/regulatory inputs not modeled\", \"Several axes (TRAF2 vesicle, TROAP, CDK5) rest on single-lab evidence\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined new kinase-independent and circuit-level roles — chromatin-accessibility-driven ACE2/DPP4 transcription enabling coronavirus entry, and an ABLIM3 synaptic substrate controlling feedforward inhibition and social behavior.\",\n      \"evidence\": \"Genome-wide CRISPR screen with kinase-dead rescue and ATAC-seq; genetic epistasis, chemogenetics, electrophysiology, and behavior in Dyrk1a+/- mice\",\n      \"pmids\": [\"37310920\", \"37797581\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How DYRK1A promotes chromatin accessibility mechanistically unresolved\", \"ABLIM3 phosphosite and direct kinase action not fully detailed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Implicated DYRK1A in Parkinson's-relevant alpha-synuclein Ser129 phosphorylation, though only via in vivo knockdown correlation.\",\n      \"evidence\": \"AAV-shRNA knockdown in a PD model with Western blot for P-alpha-synuclein and apoptosis markers\",\n      \"pmids\": [\"37469393\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Direct in vitro phosphorylation of alpha-synuclein not demonstrated\", \"Single study; correlation not causation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How DYRK1A's many competing regulatory inputs (14-3-3, PPM1B, TRAF2 ubiquitination, TROAP, proteolysis) are integrated to direct it to specific substrates and subcellular compartments in a given cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model of localization/substrate selection\", \"Kinase-dependent vs kinase-independent contributions not systematically partitioned across tissues\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 6, 8, 9, 10, 13, 17, 18, 26]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 26]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 9, 14, 23]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 9, 14, 25]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [20, 22]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [9, 13]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [6, 8, 11, 17]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 2, 14, 23]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [17, 18]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [15, 20, 28]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 24]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [14, 23]}\n    ],\n    \"complexes\": [\"DREAM complex\"],\n    \"partners\": [\"LIN52\", \"RCAN1\", \"SIRT1\", \"TRAF3\", \"TRAF2\", \"PPM1B\", \"TROAP\", \"EP300\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}